Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 crossover cardiac function study in hyperinflated COPD
2014-004680-21Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of indacaterol + glycopyrronium, indacaterol and glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Left ventricular end-diastolic volume. Started Feb 2015; status: completed.
02
Drugs
indacaterol + glycopyrroniumindacaterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-004680-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004680-21.